Navigation Links
Takeda San Francisco Enters Into A Sponsored Research Agreement With UCSF
Date:9/21/2009

SOUTH SAN FRANCISCO, Calif., Sept. 21 /PRNewswire/ -- Takeda San Francisco, Inc. (TSF), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, announced today that it has entered into a sponsored research collaboration with the University of California, San Francisco. The research program will focus on therapeutic antibody discovery and development to an undisclosed target. The agreement will solely support specific research conducted in the laboratory of Charles Craik, Ph.D., who will serve as the principal investigator for the project. This agreement enhances TSF's initiative to build a robust preclinical antibody therapeutics pipeline by leveraging the company's comprehensive and proprietary antibody technology platform and novel discovery, optimization and development technologies.

"This partnership is another example of UCSF's increasing commitment to using its world-class biomedical research programs to bring direct benefit to patients," said Dr. Regis Kelly, Executive Director of QB3, the California Institute for Quantitative Biosciences, one of four California Institutes for Science and Innovation.

"We're pleased to work with Dr. Craik, who is a leader in the field of proteases associated with disease pathogenesis," said Dr. Mary Haak-Frendscho, President and CSO of TSF. "We believe this research will help enable the discovery and development of a novel antibody product candidate to preclinical proof of concept. It furthermore demonstrates our commitment to working with academic experts concerning the development of novel biologic targets for the treatment of disease."

About Takeda San Francisco, Inc.

Takeda San Francisco, Inc. (TSF), established in November 2007 as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, is Takeda's Biologics Center of Excellence and Antibody IND Engine for human antibody therapeutics for the treatment of cancer, inflammation and metabolic diseases. TSF supports Takeda's therapeutic antibody initiative in close collaboration with Takeda's other R&D organizations. Additional information about Takeda San Francisco is available at http://www.takedasf.com.

About Takeda Pharmaceutical Company, Limited.

Founded in 1781 and located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.

About UCSF-Craik Laboratory

Dr. Charles Craik is a Professor of Pharmaceutical Chemistry at UCSF. His laboratory is focused on the role of protease structure and mechanisms of essential proteins associated with both normal and dysfunctional biological processes using novel genetic, biochemical and biophysical methods. Dr. Craik has pioneered new combinatorial technologies to probe protein-protein interaction interfaces and identify inhibitors in addition to developing an array of new expression methods to better address protein structure and function.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. For further information, please visit www.ucsf.edu.

Disclaimer

The information stated above was prepared by Takeda San Francisco and reflects solely the opinion of the company. Nothing in this statement shall be construed to imply any support or endorsement of Takeda, or any of its products, by The Regents of the University of California, its officers, agents and employees.


'/>"/>
SOURCE Takeda San Francisco, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
2. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
3. Chemizon Announces Research Collaboration Expansion With Takeda
4. Takeda submits new drug application for alogliptin (syr-322) in the US
5. Takeda Announces New U.S. Leadership
6. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
7. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
8. Takeda Completes Acquisition of Millennium
9. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
10. FDA Adds Three Months to Review of Takedas New Drug Application for TAK-390MR
11. Review of Takedas Febuxostat New Drug Application Continues Past PDUFA Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet today announces ... on the current obstacles facing infection prevention and offer strategies for the health ... these infections. , The print component of “Fighting Infection” is distributed within ...
(Date:3/24/2017)... ... ... The Radiology Business Management Association (RBMA) has named the nine winners ... year, are among the most prestigious in radiology marketing because a panel of radiology ... recognize achievements in both large budget (over $5,000) and small budget (under $5,000) campaigns. ...
(Date:3/24/2017)... ... March 24, 2017 , ... The iaedp Foundation, the premier ... professionals caring for those suffering from the full spectrum of disordered eating, announced today ... disorders professionals from nearly all 50 states and several countries converged on the Green ...
(Date:3/24/2017)... ... March 24, 2017 , ... In ... innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 ... – with nearly 2,000 consumers (and counting) already backing the campaign. , ...
(Date:3/24/2017)... ... 24, 2017 , ... On June 9, 2017, Cassie Springer ... seminar in Chicago, Illinois. She will present on: , Filing Benefit Claims—Responding ... ERISA involve claims for long-term disability benefits. This session will address the ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 24, 2017 Research and Markets has ... U.S.: Consumer Strategies" report to their offering. ... Pain Management ... and treat their physical pain, emphasizing consumer survey analysis, including ... sufferers and adults who have selected illnesses/conditions strongly associated with ...
(Date:3/24/2017)... FinancialBuzz.com News Commentary  ... According to new data published Arcview ... legal cannabis market is projected to continue to grow at ... the current presidential administration. The report created by Arcview,s data ... growth in this industry are the passage and subsequent implementation ...
(Date:3/24/2017)... A ReportsnReports.com report says, over the recent years, global ... sales of Adcetris and Kadcyla have been witnessing rapid growth after ... is driven by large number of ADC drugs in pipeline, rise ... ADCs. ... Tables and 94 Figures, 10 Major Company Profiles, spread across 154 ...
Breaking Medicine Technology: